China Universal Asset Management Co. Ltd. Increases Position in Alkermes plc (NASDAQ:ALKS)

China Universal Asset Management Co. Ltd. boosted its position in Alkermes plc (NASDAQ:ALKS) by 8.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 34,308 shares of the company’s stock after acquiring an additional 2,637 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Alkermes were worth $987,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ALKS. Loomis Sayles & Co. L P boosted its holdings in shares of Alkermes by 365.5% during the third quarter. Loomis Sayles & Co. L P now owns 1,882,936 shares of the company’s stock worth $52,704,000 after purchasing an additional 1,478,422 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in Alkermes in the 3rd quarter worth about $16,126,000. Barclays PLC grew its holdings in Alkermes by 108.8% in the 3rd quarter. Barclays PLC now owns 423,931 shares of the company’s stock valued at $11,867,000 after buying an additional 220,893 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Alkermes by 55.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 405,382 shares of the company’s stock valued at $11,347,000 after acquiring an additional 144,506 shares during the last quarter. Finally, Edgestream Partners L.P. lifted its holdings in shares of Alkermes by 218.4% during the 3rd quarter. Edgestream Partners L.P. now owns 270,671 shares of the company’s stock worth $7,576,000 after acquiring an additional 185,648 shares during the period. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Alkermes news, Director Cato T. Laurencin sold 2,691 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $31.85, for a total value of $85,708.35. Following the transaction, the director now directly owns 23,013 shares of the company’s stock, valued at $732,964.05. This represents a 10.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Christian Todd Nichols sold 5,208 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total transaction of $151,813.20. Following the sale, the senior vice president now directly owns 60,703 shares of the company’s stock, valued at $1,769,492.45. The trade was a 7.90 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 248,656 shares of company stock worth $7,807,326. 4.89% of the stock is currently owned by company insiders.

Alkermes Stock Down 1.2 %

NASDAQ ALKS opened at $31.53 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. Alkermes plc has a fifty-two week low of $22.90 and a fifty-two week high of $32.88. The business has a 50 day moving average price of $29.87 and a two-hundred day moving average price of $28.33. The stock has a market cap of $5.10 billion, a PE ratio of 16.17, a P/E/G ratio of 1.68 and a beta of 0.49.

Analyst Ratings Changes

ALKS has been the subject of several research analyst reports. The Goldman Sachs Group dropped their price target on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, October 25th. JPMorgan Chase & Co. dropped their price objective on Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Stifel Nicolaus upgraded Alkermes from a “hold” rating to a “buy” rating and lifted their target price for the company from $25.00 to $36.00 in a report on Tuesday, November 5th. Mizuho upped their price target on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $37.00 price objective on shares of Alkermes in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $36.00.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.